Shares of Rani Therapeutics Holdings (RANI) soared 32.5% to $2.18 in pre-market trading on Monday, building on Friday's remarkable 248% surge. The rally follows the announcement of a strategic partnership with Japan's Chugai Pharmaceutical (4519.T) and a

2025-10-20 15:00:56 ET

Rani Therapeutics (NASDAQ: RANI) revealed a licensing agreement with Chugai Pharmaceutical (a 60% subsidiary of Roche [RHBBY]) for its RaniPill technology. The deal was accompanied by a $60 million private placement from leading healthcare institutions. The news sent RANI shares skyrocketing nearly 250% on Friday, with an additional ~30% gain in pre-market trading on Monday.

The Chugai partnership includes a $10 million upfront payment and $18 million in near-term technology transfer milestones, along with approximately $60 million in development milestones and single-digit royalties. The initial focus of the collaboration is a next-generation hemophilia drug, Chugai's largest franchise. The agreement also includes an option to expand the use of RaniPill to up to five additional programs, potentially exceeding $1 billion in total value.

Analysts view the Chugai deal as a pivotal moment for Rani Therapeutics. Beyond providing non-dilutive funding, the partnership serves as a critical validation of the RaniPill technology, which is designed to deliver biologics such as GLP-1s. This endorsement from a major pharmaceutical player is expected to reduce perceived risks for other companies considering adoption of the technology, potentially paving the way for additional partnerships.

The timing of the Chugai deal also appears to have been instrumental in securing the $60 million private placement from prominent healthcare investors. With this new capital, Rani Therapeutics is now well-funded through 2028 and positioned to advance its lead obesity program, RT-114, into clinical trials for obese, non-diabetic patients.

Analysts highlight that the Chugai agreement not only provides crucial funding but also enhances RaniPill's credibility, which could attract further licensing opportunities. Incorporating the expected revenues from the Chugai deal and adjusting the discount rate in their valuation model from 25% to 20%, analysts have raised their 12-month price target for RANI from $5 to $10.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed the RaniPill capsules, which are a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsules. For more information, visit ranitherapeutics.com .

The post Shares of Rani Therapeutics Holdings (RANI) soared 32.5% to $2.18 in pre-market trading on Monday, building on Friday's remarkable 248% surge. The rally follows the announcement of a strategic partnership with Japan's Chugai Pharmaceutical (4519.T) and a $60.3 million private placement. appeared first on PRISM MarketView .

COMTEX_469669525/2927/2025-10-20T14:00:56